H3 Biomedicine
Show Menu
About
About Us
Our Team
Our Story
An Eisai Company
Our Culture
Science
Scientific Approach
Pipeline
Scientific Publications
Partnering
Patients
Diseases We Study
Clinical Trials
Resources
Investigational Medication
Media Relations
Press Releases
In the News
Company Information
Careers
Opportunities
Benefits
Novel SF3B1 In-Frame Deletions Result in Aberrant RNA Splicing in CLL Patients
Seeking Additional Information?
Contact